Shares of Celgene Corporation (NASDAQ:CELG) have received a consensus recommendation of “Buy” from the thirty research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and twenty-two have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $147.39.
A number of equities analysts recently weighed in on the stock. Cowen and Company reissued a “buy” rating and set a $150.00 target price on shares of Celgene Corporation in a research note on Tuesday. Vetr downgraded shares of Celgene Corporation from a “buy” rating to a “hold” rating and set a $145.17 target price for the company. in a research note on Wednesday, September 6th. BTIG Research reissued a “neutral” rating on shares of Celgene Corporation in a research note on Tuesday, September 5th. Mizuho set a $134.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a research note on Wednesday, July 26th. Finally, Cantor Fitzgerald set a $160.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a research note on Thursday, July 27th.
In other Celgene Corporation news, Director Michael D. Casey sold 9,250 shares of Celgene Corporation stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $125.59, for a total value of $1,161,707.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Rupert Vessey sold 4,785 shares of Celgene Corporation stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $120.18, for a total transaction of $575,061.30. Following the completion of the sale, the insider now directly owns 4,004 shares in the company, valued at approximately $481,200.72. The disclosure for this sale can be found here. In the last ninety days, insiders sold 263,011 shares of company stock worth $35,078,473. Insiders own 0.95% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the business. BlackRock Inc. raised its position in Celgene Corporation by 5.7% in the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after acquiring an additional 3,084,227 shares during the period. Vanguard Group Inc. raised its position in Celgene Corporation by 3.1% in the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after acquiring an additional 1,610,056 shares during the period. State Street Corp raised its position in Celgene Corporation by 2.3% in the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock worth $4,040,668,000 after acquiring an additional 723,844 shares during the period. Jennison Associates LLC raised its position in Celgene Corporation by 1.2% in the second quarter. Jennison Associates LLC now owns 13,415,734 shares of the biopharmaceutical company’s stock worth $1,742,301,000 after acquiring an additional 156,864 shares during the period. Finally, FMR LLC raised its position in Celgene Corporation by 5.9% in the second quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock worth $1,635,643,000 after acquiring an additional 697,250 shares during the period. 79.43% of the stock is currently owned by institutional investors and hedge funds.
Shares of Celgene Corporation (NASDAQ:CELG) traded up 0.82% during trading on Friday, hitting $142.07. 2,236,582 shares of the stock traded hands. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $142.64. The firm has a market capitalization of $111.15 billion, a price-to-earnings ratio of 44.00 and a beta of 1.89. The firm has a 50-day moving average of $134.40 and a 200-day moving average of $126.94.
Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.21. The firm had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The company’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same quarter last year, the firm earned $1.44 earnings per share. On average, equities analysts forecast that Celgene Corporation will post $7.32 earnings per share for the current year.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.